NCT06146660View on ClinicalTrials.gov

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

Mavacamten

According to approved product label

Trial Locations (2)

06234

TERMINATED

Local Institution - 0001, Seoul

RECRUITING

Novotech Laboratory Korea Co., Ltd., Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06146660 - A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter